Last reviewed · How we verify
NCT03795935: RESCUED
Relief From Side Effects: Clinical Use of Electrodes With Direction
NA trial testing No side-effect stimulator settings with directional lead in Deep Brain Stimulation in 6 participants. Status unknown.
1 July 2019
Quick facts
| Lead sponsor | University of British Columbia |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 6 |
| Start date | 17 September 2018 |
| Primary completion | 1 July 2019 |
| Estimated completion | 1 August 2019 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- No side-effect stimulator settings with directional lead
Conditions studied
- Deep Brain Stimulation — all drugs for Deep Brain Stimulation →
- Directional Lead — all drugs for Directional Lead →
- Essential Tremor — all drugs for Essential Tremor →
Sponsor
University of British Columbia
Who can join
Adults 18 to 80, any sex, with Deep Brain Stimulation or Directional Lead. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Deep Brain Stimulation (DBS) uses electrical pulses sent through a lead (insulated wire) to help stop unwanted symptoms in a variety of brain diseases, including the tremor seen in patients with Essential Tremor (ET). The current standard lead allows this stimulation to spread out uniformly in all directions. As these diseases progress, however, the amount of electrical stimulation required to stop the symptom usually increases. This may become problematic because the increased electrical stimulation required for advanced symptoms may spread outside the desired targeted area, and effect other parts of the brain and causing unwanted side effects. A new type of DBS lead has been developed which can steer, or focus, the electrical stimulation in a given direction toward the desired target area and away from areas that would cause side effects. We would like to quantify the benefit seen in patients who have been switched from the traditional lead to this new directional lead.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Deep Brain Stimulation for the Management of Refractory Neurological Disorders: A Comprehensive Review.
Rissardo JP, Vora NM, Tariq I, Mujtaba A, et al · · 2023 · cited 17× · PMID 38004040 · DOI 10.3390/medicina59111991
Verify or expand the search:
- PubMed search for NCT03795935
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Deep Brain Stimulation
Currently open trials in the same condition.
- NCT07376278 — Predictors of Clinical Outcomes of Deep Brain Stimulation in Parkinson's Disease · recruiting
- NCT06909045 — Adaptive vs. Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease · NA · recruiting
- NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
- NCT07176494 — Revision of Deep Brain Stimulator in Patients With Parkinson's Disease · NA · recruiting
- NCT06960096 — Cognitive Decline Following Deep Brain Stimulation: A DBS-fMRI Study · recruiting
Other University of British Columbia trials
Trials by the same sponsor.
- NCT07340970 — Sensory Stimuli During Cesarean Delivery · not yet recruiting
- NCT07481201 — Phenylalanine Requirements in the Menstrual Phases · NA · not yet recruiting
- NCT07492095 — Leucine Requirements in School-Age Children · NA · not yet recruiting
- NCT07429305 — Combined Tibial Nerve Stimulation and Standing for People With SCI · NA · recruiting
- NCT07519928 — Exploring the Feasibility and Benefits of Implementing Pelvic Floor Muscle Training During Inpatient Rehabilitation for · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03795935 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of British Columbia
- Last refreshed: 8 January 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03795935.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing